Literature DB >> 16918705

An optimized method for the functional analysis of human regulatory T cells.

H-H Oberg1, D Wesch, J Lenke, D Kabelitz.   

Abstract

Naturally occurring regulatory T cells (Treg) suppress the activation of antigen-responsive T cells in a cell contact-dependent manner. In order to investigate the impact of soluble mediators and receptor-ligand interactions on the interplay between naive T cells and Treg, a reproducible suppressor cell assay which functions in the absence of additional feeder cells or antigen-presenting cells is mandatory. Here, we describe such a method which is suited to study the modulation of responder T cell/Treg interactions in vitro. Treg were isolated from negatively purified total human CD4+ T cells by positive selection using anti-CD25 monoclonal antibody (MoAb)-coated Dynabeads followed by a detachment step. The remaining CD4+ CD25- responder T cells were cocultured with CD4+ CD25+ Treg in the presence of T-cell Activation/Expansion Beads from Miltenyi Biotec pre-coated with anti-CD3 plus anti-CD28 monoclonal antibody (MoAb). The optimal concentration for coating was 5 microg/ml for both MoAb. At this concentration, strong proliferation of responder T cells was elicited which was almost completely suppressed by Treg at 1:1 cell ratios. When higher concentrations of anti-CD3/anti-CD28 MoAb were used for coating, Treg also showed some degree of proliferation. The optimized suppressor assay proved to be highly reproducible and was used here to confirm the partial or complete reversal of Treg-mediated T-cell suppression by some cytokines (IL-2, IL-15), soluble IL-6 receptor/IL-6 fusion protein and recombinant GITR-ligand. Furthermore, our data confirm that Treg do not need other cell types to suppress proliferation of CD4+ CD25- responder T cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16918705     DOI: 10.1111/j.1365-3083.2006.01825.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  9 in total

1.  In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy.

Authors:  James C Lee; Erik Hayman; Hollie J Pegram; Elmer Santos; Glenn Heller; Michel Sadelain; Renier Brentjens
Journal:  Cancer Res       Date:  2011-04-12       Impact factor: 12.701

2.  Antagonistic and agonistic anti-canine CD28 monoclonal antibodies: tools for allogeneic transplantation.

Authors:  Scott S Graves; Diane M Stone; Carol Loretz; Laura J Peterson; Marina Lesnikova; Billanna Hwang; George E Georges; Richard Nash; Rainer Storb
Journal:  Transplantation       Date:  2011-04-27       Impact factor: 4.939

3.  Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma.

Authors:  R Cabrera; M Ararat; E A Eksioglu; M Cao; Y Xu; C Wasserfall; M A Atkinson; C Liu; D R Nelson
Journal:  Scand J Immunol       Date:  2010-10       Impact factor: 3.487

4.  Phenotypic and Functional Studies of Human Treg Cell Subpopulations.

Authors:  Mo Atif; Mustapha Cherai; Makoto Miyara
Journal:  Methods Mol Biol       Date:  2023

5.  Regulatory T cells and their role in rheumatic diseases: a potential target for novel therapeutic development.

Authors:  Diana Milojevic; Khoa D Nguyen; Diane Wara; Elizabeth D Mellins
Journal:  Pediatr Rheumatol Online J       Date:  2008-12-01       Impact factor: 3.054

6.  Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy.

Authors:  Tihamer Orban; Klara Farkas; Heyam Jalahej; Janos Kis; Andras Treszl; Ben Falk; Helena Reijonen; Joseph Wolfsdorf; Alyne Ricker; Jeffrey B Matthews; Nadio Tchao; Peter Sayre; Pete Bianchine
Journal:  J Autoimmun       Date:  2010-06       Impact factor: 7.094

7.  Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.

Authors:  Thomas Schwaab; Adrian Schwarzer; Benita Wolf; Todd S Crocenzi; John D Seigne; Nancy A Crosby; Bernard F Cole; Jan L Fisher; Jill C Uhlenhake; Diane Mellinger; Cathy Foster; Zbigniew M Szczepiorkowski; Susan M Webber; Alan R Schned; Robert D Harris; Richard J Barth; John A Heaney; Randolph J Noelle; Marc S Ernstoff
Journal:  Clin Cancer Res       Date:  2009-07-21       Impact factor: 12.531

8.  Regulatory T-cells and associated pathways in metastatic renal cell carcinoma (mRCC) patients undergoing DC-vaccination and cytokine-therapy.

Authors:  Adrian Schwarzer; Benita Wolf; Jan L Fisher; Thomas Schwaab; Sven Olek; Udo Baron; Craig R Tomlinson; John D Seigne; Nancy A Crosby; Jiang Gui; Thomas H Hampton; Camilo E Fadul; John A Heaney; Marc S Ernstoff
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

9.  Phenotype and regulation of immunosuppressive Vδ2-expressing γδ T cells.

Authors:  Christian Peters; Hans-Heinrich Oberg; Dieter Kabelitz; Daniela Wesch
Journal:  Cell Mol Life Sci       Date:  2013-10-04       Impact factor: 9.261

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.